First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study.

被引：0
|
作者：
Niho, S [1 ]
Kubota, K [1 ]
Goto, K [1 ]
Yoh, K [1 ]
Ohmatsu, H [1 ]
Kakinuma, R [1 ]
Nishiwaki, Y [1 ]
机构：
[1] Natl Canc Ctr Hosp E, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7059
引用
收藏
页码：631S / 631S
页数：1
相关论文
共 50 条
  • [1] A phase II study of first-line single agent of gefitinib in patients (pts) with stage IV non-small cell lung cancer (NSCLC).
    Suzuki, R
    Hasegawa, Y
    Baba, K
    Saka, H
    Saito, H
    Taniguchi, H
    Yamamoto, M
    Matsumoto, S
    Kato, K
    Shimokata, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 640S - 640S
  • [2] First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study
    Niho, S
    Kubota, K
    Goto, K
    Yoh, K
    Ohmatsu, H
    Kakinuma, R
    Saijo, N
    Nishiwaki, Y
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 64 - 69
  • [3] Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer
    Yongmei Yin Yiting Geng Xiaodong Li Xiaoli Hu Xiaofeng Chen Wei Li Yongqian Shu Department of Oncology the First Affiliated Hospital of Nanjing Medical University Nanjing China
    [J]. Journal of Nanjing Medical University, 2009, 23 (06) : 392 - 397
  • [4] Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer
    Yongmei Yin1
    [J]. The Journal of Biomedical Research, 2009, (06) : 392 - 397
  • [5] First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
    Yin Y.-M.
    Geng Y.-T.
    Shao Y.-F.
    Hu X.-L.
    Li W.
    Shu Y.-Q.
    Wang Z.-X.
    [J]. Journal of Experimental & Clinical Cancer Research, 29 (1)
  • [6] First-Line Single Agent Treatment With Gefitinib in Advanced Non-Small-Cell Lung Cancer Patients
    Yin, Yong-mei
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (05) : 325 - 325
  • [7] Phase II trial of docetaxel and gefitinib as first-line therapy for elderly patients with advanced non-small cell lung cancer (ANSCLC).
    Williams, CC
    Haura, EB
    Antonia, SJ
    Chiappori, A
    Bepler, G
    Simon, GR
    Moffitt, HL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 701S - 701S
  • [8] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
    Ji, Y.
    Wang, X.
    Lou, Z.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
  • [9] Phase II study of meloxicam with carboplatin plus docetaxel in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
    Ishida, T.
    Kanazawa, K.
    Oizumi, H.
    Yokouchi, H.
    Yamazaki, K.
    Akie, K.
    Sukoh, N.
    Harada, M.
    Munakata, M.
    Isobe, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] A new docetaxel (D) gemcitabine (G) regimen as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): A phase II study.
    Morere, JF
    Terrioux, P
    Brechot, JM
    Tredaniel, J
    Bouchahda, M
    Duhamel, JP
    Mandet, J
    Brain, E
    Beerblock, K
    Fellague, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 692S - 692S
12345